Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Interventional Dementia Study

This study is currently closed to enrollment.

Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene

woman and physician with masks on 
AGE: 25 – 85 years old
TYPE: Interventional Drug Study
CONDITION: Frontotemporal Lobar Degeneration/Frontotemporal Dementia
LOCATIONS: UH Cleveland Medical Center, UH Brain Health and Memory Center

Purpose of the Study

The purpose of this Phase 3 study is to determine if the experimental drug AL001 is effective and safe in treating individuals who have a progranulin gene mutation that causes Frontotemporal Dementia (FTD), when compared to placebo (a solution that contains no active AL001 drug).

Study ID: